NORD Issues Statement on Departure of FDA Commissioner Margaret Hamburg
Wednesday, February 11th, 2015
WASHINGTON, D.C.—February 11, 2015
The following statement was issued today by Peter L. Saltonstall, President and CEO of NORD, following the announcement by FDA Commissioner Margaret Hamburg, M.D., that she will leave her job at the end of March:
Dr. Hamburg has been an ardent and sincere supporter of the rare disease community and orphan drug issues since becoming FDA Commissioner six years ago. She has spoken at a number of our meetings, most recently as keynoter at our Summit last October. I recall in particular her participation several years ago in one of our patient forums when she demonstrated compassion and understanding for the special challenges faced by patients with rare diseases.
Her tenure at FDA has been positive for the rare disease community. We at NORD have worked more closely with FDA than ever before on issues of mutual interest.
I wish Dr. Hamburg well as she pursues new interests and look forward to continuing our productive relationship with the FDA leadership.
For more information about NORD, visit http://campaigns.rarediseases.us/t/r-l-qeqtd-trwttydb-f/